Several other equities analysts have also issued reports on LXRX. Wedbush set a $175.00 price target on Lululemon Athletica and gave the company a hold rating in a research note on Tuesday, June 11th. Needham & Company LLC boosted their price target on Alteryx to $108.00 and gave the company a buy rating in a research note on Thursday, May 2nd. Zacks Investment Research downgraded Hanger from a hold rating to a sell rating in a report on Tuesday, May 28th. Stifel Nicolaus set a $99.00 price objective on C.H. Robinson Worldwide and gave the company a hold rating in a report on Monday, March 25th. Finally, Gabelli raised Lexicon Pharmaceuticals from a sell rating to a hold rating in a report on Monday, March 25th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and an average target price of $16.38.
LXRX remained flat at $$6.20 on Thursday. The company had a trading volume of 217,445 shares, compared to its average volume of 281,014. Lexicon Pharmaceuticals has a 1 year low of $4.25 and a 1 year high of $13.31. The stock has a market cap of $658.89 million, a P/E ratio of -5.44 and a beta of 0.84. The firm has a 50 day simple moving average of $5.91.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $9.20 million for the quarter, compared to the consensus estimate of $13.26 million. During the same quarter in the prior year, the firm earned ($0.40) earnings per share. The company’s revenue was down 63.8% on a year-over-year basis. On average, analysts expect that Lexicon Pharmaceuticals will post -0.47 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXRX. First Manhattan Co. acquired a new stake in Lexicon Pharmaceuticals during the first quarter valued at approximately $15,282,000. Pictet Asset Management Ltd. boosted its holdings in shares of Lexicon Pharmaceuticals by 42.6% in the 1st quarter. Pictet Asset Management Ltd. now owns 586,850 shares of the biopharmaceutical company’s stock worth $3,263,000 after acquiring an additional 175,400 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its holdings in shares of Lexicon Pharmaceuticals by 181.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock worth $1,783,000 after acquiring an additional 173,096 shares in the last quarter. Norges Bank acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $1,005,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Lexicon Pharmaceuticals by 70.0% in the 4th quarter. Two Sigma Investments LP now owns 313,877 shares of the biopharmaceutical company’s stock worth $2,084,000 after acquiring an additional 129,215 shares in the last quarter. 98.29% of the stock is currently owned by institutional investors.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: How is a price target determined?
Receive News & Ratings for Lexicon Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.